作为治疗原发性高血压的低级特拉古斯刺激:一种具有更广泛心脏保护潜力的全身反应?
1Institute for Pathophysiology, West German Heart and Vascular Centre, University of Essen Medical School, University of Duisburg-Essen, Essen, Germany.
Journal of neurophysiology
|January 27, 2025
概括
低级特拉古斯刺激 (LL-TS) 是一种非药物方法来刺激迷走神经 (VNS). 这种技术有望降低血压,并提供潜在的心脏保护益处.
科学领域:
- 自主神经系统研究自主神经系统研究
- 心血管疾病机制的心血管疾病机制
- 非侵袭性神经调节是一种非侵袭性神经调节.
背景情况:
- 自主神经系统 (ANS) 在心血管调节中起着至关重要的作用.
- 该系统的不平衡与高血压和其他心血管疾病有关.
- 神经刺激 (VNS) 是管理与ANS相关的疾病的一个感兴趣领域.
研究的目的:
- 探索低级别的尾神经刺激 (LL-TS) 作为一种非侵入性迷走神经刺激 (VNS) 方法.
- 研究LL-TS的潜在心脏保护作用.
- 评估LL-TS对高血压患者血压的影响.
主要方法:
- 使用低级别的气刺激 (LL-TS) 作为一种非侵入性技术.
- 应用LL-TS来触发复杂的系统反应.
- 在高血压患者中观察LL-TS的影响.
主要成果:
- 低级特拉古斯刺激 (LL-TS) 证明了血压 (BP) 的降低.
- LL-TS作为一种非药物基础的,易于应用的工具,用于潜在的ANS调制.
- 这些发现表明,LL-TS的心脏保护潜力比最初预期的更大.
结论:
- LL-TS是一种有前途的非侵入性方法,用于迷走神经刺激 (VNS).
- 在管理高血压和相关心血管疾病方面,LL-TS可能会带来显著的好处.
- 对LL-TS的进一步研究可以扩大其在自主神经系统 (ANS) 和心血管健康中的应用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:17Antihypertensive Drugs: Action of β1 Blockers
305
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
305
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
574
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574
01:18Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
01:23Antihypertensive Drugs: Vasodilators
464
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
464